全國服務咨詢熱線：
18860915427
18860915427
產品分類
Product Category詳細介紹
| 品牌 | absin | CAS | 73963-72-1 |
|---|---|---|---|
| 分子式 | C20H27N5O2 | 純度 | 99% |
| 分子量 | 369.46 | 貨號 | abs47027080 |
| 規格 | 10mg | 供貨周期 | 現貨 |
| 主要用途 | used in the alleviation of the symptom o | 應用領域 | 化工,生物產業,農林牧漁,制藥/生物制藥,綜合 |
Cilostazol 73963-72-1
| 產品描述 | |
| 描述 | Cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease. |
| 純度 | 99% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 西luo他唑; OPC 13013 |
| 外觀 | off-white solid |
| 可溶性/溶解性 | DMSO : 50 mg/mL (135.33 mM; Need ultrasonic) |
| 生物活性 | |
| 靶點 | PDE3 |
| In vitro(體外研究) | Cilostazol (OPC-13013) is a 2-oxo-quinoline derivative with antithrombotic, vasodilator, antimitogenic and cardiotonic properties. The vasodilatory and antiplatelet actions of cilostazol are due mainly to the inhibition of phosphodiesterase 3 (PDE3) and subsequent elevation of intracellular cAMP levels. Cilostazol inhibits platelet aggregation. Cilostazol also possesses the ability to inhibit adenosine uptake. Elevation of interstitial adenosine by cilostazol in the heart is shown to reduce increases in cAMP caused by the PDE3-inhibitory action of cilostazol, thus attenuating the cardiotonic effects. Cilostazol is reported to inhibit smooth muscle cell proliferation. Cilostazol relaxes vascular smooth muscle and causes vasodilatation. Cilostazol inhibits the cytokine-induced expression of monocyte chemoattractant protein-1 (MCP-1). Cilostazol reduced plasma triglycerides and raised plasma HDL-cholesterol . |
| In vivo(體內研究) | Cilostazol (clinically used doses; p.o.; for 2 weeks) could alleviate CCl4 -induced hepatic fibrogenesis in vivo, presumably due to its direct effect to suppress HSC activation. Cilostazol (intraperitoneal injection; 10 mg/kg; 7 consecutive days after ischemia) attenuates neurological dysfunctions, brain atrophy and infarct volume, and inhibits astrocyte proliferation/glial scar formation and accelerated the angiogenesis in the ischemic boundary zone 7 and 28 days after ischemia. |
| 研究領域 | |
| 研究領域 | Signal TransductionMetabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產品咨詢
電話
微信掃一掃
地址：上海市浦東新區新浩路58號申江科創園18棟
郵箱：fengmj@univ-bio.com
傳真：